Cardiovascular Risks of Anemia Correction with Erythrocyte Stimulating Agents: Should Blood Viscosity Be Monitored for Risk Assessment?

Author： Jeong Seul-Ki   Cho Young   Duey Marc   Rosenson Robert  

Publisher： Springer Publishing Company

ISSN： 0920-3206

Source： Cardiovascular Drugs and Therapy, Vol.24, Iss.2, 2010-04, pp. : 151-160

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

By Del Vecchio Lucia   Locatelli Francesco  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 923-931

Informa Healthcare

Access to resources Recommend Favorite

Metabolic Syndrome: Cardiovascular Risk Assessment and Management

By Wong Nathan D.  

American Journal of Cardiovascular Drugs, Vol. 7, Iss. 4, 2007-01 ,pp. : 259-272

Adis International

Access to resources Recommend Favorite

The Role of Neopterin in Atherogenesis and Cardiovascular Risk Assessment

By  

Current Medicinal Chemistry, Vol. 16, Iss. 35, 2009-12 ,pp. : 4644-4653

Bentham Science Publishers

Access to resources Recommend Favorite

A Benefit-Risk Assessment of Class III Antiarrhythmic Agents

By Brendorp B.  

Drug Safety, Vol. 25, Iss. 12, 2002-01 ,pp. : 847-865

Adis International

Access to resources Recommend Favorite

A benefit–risk assessment of class III antiarrhythmic agents

By Elming Hanne   Brendorp Bente   Pehrson Steen   Pedersen Ole Dyg   Køber Lars   Torp-Petersen Christian  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 559-577

Informa Healthcare

Access to resources Recommend Favorite